Akums Drugs

Why is Akums Drugs & Pharmaceuticals Ltd falling/rising?

As of 06-Aug, Akums Drugs & Pharmaceuticals Ltd's stock price is declining at 662.45, down -0.54%, due to reduced investor participation and consecutive declines over three days. Despite a strong annual return of 35.48%, a -16% drop in profits raises investor concerns, contributing to the current downward trend.

As of 06-Aug, Akums Drugs & Pharmaceuticals Ltd is experiencing a decline in its stock price, currently at 662.45, which reflects a change of -3.6 (-0.54%). This decrease can be attributed to several factors. The stock has underperformed its sector by -0.98% today and has been on a consecutive decline for the last three days, accumulating a total drop of -3.09% during this period. Additionally, there has been a notable decrease in investor participation, with delivery volume falling by -44.86% compared to the 5-day average, indicating reduced trading interest.<BR><BR>Despite the stock's strong performance over the past year, generating a return of 35.48% compared to the market's 4.47%, the company's profits have decreased by -16%. This discrepancy between stock performance and profit decline may contribute to investor concerns, leading to the current downward trend. Furthermore, while the stock is trading at a discount compared to its peers' average historical valuations, the recent price movements and falling investor participation suggest a cautious sentiment among investors.

Which are the latest news on Akums Drugs?

When is the next results date for Akums Drugs & Pharmaceuticals Ltd?

The next results date for Akums Drugs & Pharmaceuticals Ltd is August 8, 2026.

The next results date for Akums Drugs & Pharmaceuticals Ltd is scheduled for August 8, 2026.

What does Akums Drugs do?

Akums Drugs and Pharmaceuticals Ltd is a pharmaceutical contract development and manufacturing organization, incorporated in 2004, with a market cap of INR 8,810 Cr and reported net sales of 1,158 Cr and net profit of 85 Cr for the quarter ending March 2026. Key metrics include a P/E ratio of 35.00 and a return on equity of 8.11%.

Overview: <BR>Akums Drugs and Pharmaceuticals Ltd is a pharmaceutical contract development and manufacturing organization (CDMO) operating in the Pharmaceuticals & Biotechnology industry within the small-cap market segment.<BR><BR>History: <BR>The company was incorporated on April 19, 2004, and received its Certificate for Commencement of Business on May 13, 2004. The latest quarterly results report net sales and profit for the period ending March 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 1,158 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 85 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 8,810 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 35.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.46 <BR>Return on Equity: 8.11% <BR>Price to Book: 2.58 <BR><BR>Contact Details: <BR>No Company Details Available <BR>Registrar Address: Not available.

How big is Akums Drugs?

As of 10th June, Akums Drugs & Pharmaceuticals Ltd has a market capitalization of 8,810.00 Cr and reported net sales of 4,359.02 Cr and a net profit of 255.19 Cr over the latest four quarters.

As of 10th June, <BR><BR>Market Cap: Akums Drugs & Pharmaceuticals Ltd has a market capitalization of 8,810.00 Cr, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 4,359.02 Cr, while the sum of Net Profit for the same period is 255.19 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the balance sheet is March 2025. Shareholder's Funds stand at 3,047.01 Cr, and Total Assets are valued at 3,905.38 Cr.

Who are the peers of the Akums Drugs?

Akums Drugs' peers include Shilpa Medicare, Sanofi Consumer, P & G Health Ltd, Strides Pharma, Blue Jet Health, Supriya Lifesci., Sanofi India, and SPARC. In terms of management risk, growth, and capital structure, Akums Drugs shows average performance, with a 1-year return of 5.85%, higher than Sanofi India but lower than Supriya Lifesci.

Peers: The peers of Akums Drugs are Shilpa Medicare, Sanofi Consumer, P & G Health Ltd, Strides Pharma, Blue Jet Health, Supriya Lifesci., Sanofi India, and SPARC.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sanofi Consumer, P & G Health Ltd, and Sanofi India, while Good management risk is found at Blue Jet Health and Supriya Lifesci. Average management risk is present at Akums Drugs, Strides Pharma, and SPARC, and Below Average management risk is noted at Shilpa Medicare. In terms of Growth, Excellent growth is seen at SPARC, while Below Average growth is noted at Shilpa Medicare, Sanofi Consumer, P & G Health Ltd, Akums Drugs, Strides Pharma, Blue Jet Health, Supriya Lifesci., Sanofi India, and the rest. For Capital Structure, Excellent capital structure is attributed to Sanofi Consumer, P & G Health Ltd, Blue Jet Health, and Supriya Lifesci., while Good capital structure is noted at Akums Drugs, and Below Average capital structure is observed at Shilpa Medicare, Strides Pharma, and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Supriya Lifesci. at 43.14%, while the peer with the lowest is Sanofi India at -48.68%. Akums Drugs has a 1-year return of 5.85%, which is higher than Sanofi India but lower than Supriya Lifesci. Additionally, Blue Jet Health and Sanofi India have negative six-month returns.

Are Akums Drugs & Pharmaceuticals Ltd latest results good or bad?

Akums Drugs & Pharmaceuticals Ltd's latest results show a mixed performance: while net profit increased by 27.58% quarter-on-quarter, it declined 42.68% year-on-year. Revenue saw a slight decrease from the previous quarter but a 9.69% increase year-on-year, and the low return on equity indicates ongoing challenges, suggesting investors should proceed with caution.

Akums Drugs & Pharmaceuticals Ltd's latest results present a mixed picture. In Q4 FY26, the company reported a net profit of ₹84.61 crore, which is a significant 27.58% increase compared to the previous quarter. However, this figure represents a concerning 42.68% decline year-on-year, highlighting ongoing challenges.<BR><BR>On the revenue front, net sales for the quarter were ₹1,157.87 crore, showing a slight decrease of 0.15% from the previous quarter but a healthy increase of 9.69% compared to the same quarter last year. The operating margin improved to 13.10%, the highest in seven quarters, indicating better operational efficiency.<BR><BR>While the quarterly performance shows some positive trends, particularly in terms of margin expansion, the year-on-year profit decline raises red flags about the company's overall health and ability to sustain growth. Additionally, the return on equity (ROE) remains low at 9.70%, which is below the industry average, suggesting that the company is struggling to generate strong returns on its capital.<BR><BR>In summary, while there are some positive indicators in the latest results, the significant year-on-year profit drop and low ROE suggest that Akums Drugs is facing challenges that could impact its future performance. Investors may want to approach with caution, monitoring for sustained improvements in revenue and profitability.

Should I buy, sell or hold Akums Drugs & Pharmaceuticals Ltd?

How has been the historical performance of Akums Drugs?

Akums Drugs has shown significant recovery and growth, with net sales reaching 4,118.16 crore in March 2025, up from 3,654.82 crore in March 2023, and a profit after tax of 343.78 crore, recovering from a loss the previous year. The company's financial position is stable, with improved cash flow and earnings per share increasing to 22.09.

Answer:<BR>The historical performance of Akums Drugs shows a significant recovery and growth in recent years, particularly in the fiscal year ending March 2025.<BR><BR>Breakdown:<BR>In the fiscal year ending March 2025, Akums Drugs reported net sales of 4,118.16 crore, slightly down from 4,178.18 crore in March 2024 but up from 3,654.82 crore in March 2023. The total operating income mirrored the net sales at 4,118.16 crore for March 2025. The company's total expenditure decreased to 3,653.67 crore in March 2025 from 4,055.20 crore in March 2024, contributing to an operating profit (PBDIT) of 516.61 crore, a substantial increase from 157.01 crore in the previous year. Profit before tax turned positive at 345.25 crore in March 2025, recovering from a loss of 45.28 crore in March 2024, while profit after tax surged to 343.78 crore compared to just 0.79 crore in the prior year. The consolidated net profit also reflected this positive trend, reaching 338.18 crore in March 2025, a recovery from a loss of 4.04 crore in March 2024. The company's earnings per share (EPS) improved significantly to 22.09 in March 2025 from -0.28 in March 2024. On the balance sheet, total assets increased to 3,905.38 crore in March 2025 from 3,393.30 crore in March 2024, while total liabilities rose to 3,905.38 crore from 3,393.30 crore, indicating a stable financial position. The cash flow from operating activities also improved to 498 crore in March 2024, compared to 176 crore in March 2023, showcasing better cash generation capabilities. Overall, Akums Drugs demonstrated a strong recovery and growth trajectory in its financial performance over the past few years.

Is Akums Drugs technically bullish or bearish?

As of October 10, 2025, Akums Drugs shows a mildly bearish trend due to bearish weekly MACD and KST, despite bullish weekly and monthly RSI readings indicating some underlying strength.

As of 10 October 2025, the technical trend for Akums Drugs has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by the weekly MACD and KST being bearish, alongside daily moving averages indicating a bearish trend. However, the weekly and monthly RSI readings are bullish, suggesting some underlying strength. The Bollinger Bands and OBV are also mildly bearish on a weekly basis. Overall, while there are bullish signals from the RSI, the prevailing indicators lean towards a mildly bearish outlook.

Who are the top shareholders of the Akums Drugs?

The top shareholders of Akums Drugs include Akums Master Trust (40.79%), mutual funds (6.11%), foreign institutional investors (5.77%), and Ruby Qc Investment Holdings Pte Ltd (4.62%), with individual investors holding 3.41%. There are no pledged promoter holdings.

The top shareholders of Akums Drugs include the promoters, with Akums Master Trust, represented by Sanjeev Jain and Sandeep Jain, holding the largest share at 40.79%. There are no pledged promoter holdings. Additionally, mutual funds hold a total of 6.11% across 18 schemes, and foreign institutional investors (FIIs) account for 5.77% through 50 different FIIs. The highest public shareholder is Ruby Qc Investment Holdings Pte Ltd, which holds 4.62%. Individual investors collectively own 3.41% of the company.

Is Akums Drugs overvalued or undervalued?

As of May 28, 2025, Akums Drugs is considered an attractive investment due to its undervalued status, with a PE ratio of 27.65, lower than peers like Sun Pharmaceutical and Divi's Laboratories, despite a year-to-date return of -11.07% compared to the Sensex's 5.54%.

As of 28 May 2025, the valuation grade for Akums Drugs has moved from does not qualify to attractive, indicating a significant improvement in its investment appeal. The company is currently assessed as undervalued. Key ratios include a PE ratio of 27.65, an EV to EBITDA of 18.09, and a ROCE of 12.16%. <BR><BR>In comparison to its peers, Akums Drugs has a lower PE ratio than Sun Pharmaceutical Industries Ltd., which stands at 35.25, and Divi's Laboratories Ltd., which is at 79.33. Other attractive peers include Cipla Ltd. with a PE of 22.99 and Dr. Reddy's Laboratories Ltd. at 19.49, further supporting the notion that Akums Drugs is undervalued within its sector. Despite a recent underperformance compared to the Sensex, with a year-to-date return of -11.07% against the Sensex's 5.54%, the company's valuation metrics suggest a favorable investment opportunity.

Has Akums Drugs declared dividend?

No Dividend History Available